Alyeska Investment Group
VNDA icon

Alyeska Investment Group’s Vanda Pharmaceuticals VNDA Stock Holding History

Alyeska Investment Group’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-163,676
Closed -$2.08M – 534
2015
Q2 		$2.08M Sell
163,676
-38,540
-19% -$416K 0.02% 345
2015
Q1 		$1.88M Sell
202,216
-77,784
-28% -$879K 0.03% 379
2014
Q4 		$4.01M Buy
280,000
+107,839
+63% +$1.28M 0.07% 285
2014
Q3 		$1.79M Buy
172,161
+122,695
+248% +$1.61M 0.04% 300
2014
Q2 		$800K Buy
+49,466
New +$659K 0.02% 359
2013
Q4 		– Sell
-150,500
Closed -$1.65M – 381
2013
Q3 		$1.65M Buy
+150,500
New +$1.61M 0.07% 239

Other funds holding VNDA

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Alyeska Investment Group's VNDA Position: Q3 2015 in Review

Alyeska Investment Group sold out of Vanda Pharmaceuticals (VNDA) in Q3 2015, closing a stake of 163,676 shares — an estimated $2.08M sold.

Alyeska Investment Group first reported a position in VNDA in Q3 2013 and held it in 6 quarters. The position peaked at $4.01M in Q4 2014. 122 funds tracked by Wall St. Rank hold VNDA as of Q3 2015.

  • Alyeska Investment Group reported no remaining Vanda Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Alyeska Investment Group sold 163,676 Vanda Pharmaceuticals shares in Q3 2015, an estimated $2.08M.
  • Alyeska Investment Group first reported a position in Vanda Pharmaceuticals in Q3 2013 and held it in 6 quarters.
  • Alyeska Investment Group's Vanda Pharmaceuticals position peaked at $4.01M in Q4 2014.
  • 122 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2015.

Based on Alyeska Investment Group's 13F filing for Q3 2015, filed 16 Nov 2015.